The effect and mechanism of regulating autophagy related signaling pathways on the sensitivity of stereotactic radiotherapy for recurrent high-grade gliomas

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2400079349

Enrollment

Unknown

Registered

2024-01-01

Start date

2024-01-01

Completion date

Unknown

Last updated

2024-01-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Recurrent high-grade gliomas

Interventions

Group A:Stereotactic radiotherapy 35Gy

Group B:Stereotactic radiotherapy 30Gy

Group C:Stereotactic radiotherapy 27Gy

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: All patients were ranged from 18 to 75 years old; patients were diagnosed pathologically with WHO III-IV glioma; The maximum diameter of the tumor is = 3cm, and the number of recurrent lesions is = 3; Normal organs function (heart, liver, lungs, kidneys, bone marrow, etc.) tolerate stereotactic radiotherapy.

Exclusion criteria

Exclusion criteria: metastasis; Pregnance or lactating; patients had other serious systemic diseases or synchronous multiple primary malignancies; The volume of recurrent lesions is too large (the maximum diameter of the tumor is greater than 3cm) or the number of recurrent lesions is greater than 3.

Design outcomes

Primary

Measure	Time frame
Objective response rate ;	—

Secondary

Measure	Time frame
Progression-free survival;oral survival;	—

Countries

China

Contacts

Public ContactLiu Feng

Department of Radiation Oncology, Hunan Cancer Hospital

liufeng820111@163.com+86 186 1398 5727

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026